"We know the devil will be in the detail and there is a huge amount of work ahead in negotiating and defining how we implement the reforms that are so urgently needed," said Medicines Australia chief executive and HTA review reference committee member Liz de Somer.
Medicines Australia says the 'devil is in the detail' of HTA review options paper
January 29, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News
